SAN FRANCISCO—Serial measurements of cardiac troponin using an investigational high-sensitivity assay enhanced risk stratification for cardiovascular disease and heart failure in patients with stable ischemic heart disease, according to an analysis of the PROVE IT-TIMI 22 study, presented March 9 at the American College of Cardiology’s (ACC) scientific session.
